Role of pleural fluid interleukin-6, neutrophil-lymphocyte ratio, and monocyte-lymphocyte ratio in distinguishing tuberculous and malignant pleural effusions

Venny Singgih¹*, Ketut Suryana², Ida Ayu Jasminarti Dwi Kusumawardani¹, Ni Wayan Candrawati¹, I. Gede Ketut Sajinadiyasa¹, Ida Bagus Ngurah Rai¹

INTRODUCTION

Pleural effusion is a common respiratory disorder and its presence increases morbidity. In the United States, an estimated 1.5 million people suffer from pleural effusions each year, with the most common causes being congestive heart disease, parapneumonic pleural effusions, and malignant pleural effusions.¹ In countries with high prevalence of tuberculosis, including Indonesia, tuberculous pleural effusion is one of the main causes of pleural effusion. Research by Surjanto et al in Surakarta in 2012, 57.01% of pleural effusion patients were unilateral pleural effusions, and the most common etiology was malignancy (33.64%) and followed by tuberculosis (30.84%).² At Sanglah General Hospital, Denpasar in 2013, the cause of pleural effusions were malignancy (34.6%), pneumonia (15%), and tuberculosis (10.3%).³ Determining the etiology of pleural effusion is still a challenge. Tuberculous pleural effusions often present

ABSTRACT

Background: Pleural effusion is caused by various disease, including tuberculosis infection and malignancy. To determine the etiology, immunologic parameters are needed to distinguish tuberculous and malignant pleural effusions, including pleural fluid interleukin-6 (IL-6), neutrophil-lymphocyte ratio (NLR), and monocyte-lymphocyte ratio (MLR).

Methods: This was a cross-sectional study, conducted at Sanglah General Hospital in Denpasar from March 2020 to September 2020. Pleural fluid IL-6 and leucocyte differential count were measured from subjects with tuberculous and malignant pleural effusions.

Results: There were 22 tuberculous pleural effusion subjects with mean pleural fluid IL-6 9269.017±902.211 pg/ml, median (range) pleural fluid NLR 0.123 (0.044-9.449), and MLR 0.065 (0.044-0.355). There were 31 subjects with malignant pleural effusions, with mean pleural fluid IL-6 8212.146±2022.350 pg/ml, median pleural fluid NLR 0.189 (0.015-2.599), and MLR 0.065 (0.010-0.254). Pleural fluid IL-6 in tuberculous pleural effusions were significantly higher (p=0.014). With a pleural fluid IL-6 cut-off ≥9147.959 pg/ml, sensitivity of 63.6% and specificity of 64.5% were obtained. Pleural fluid NLR and MLR of the two groups were not significantly different (p=0.807 and p=0.116).

Conclusions: Pleural fluid IL-6 in tuberculous pleural effusions is higher than malignant pleural effusions, with a cut-off of ≥9147.959 pg/ml, tuberculous pleural effusions can be diagnosed with sensitivity of 63.6% and specificity of 64.5%. There is no difference in pleural fluid NLR and MLR in tuberculous and malignant pleural effusions.

Keywords: Interleukin-6, Tuberculous pleural effusions, Malignant pleural effusions
Patients with tuberculous pleural effusions were patients who experienced pleural effusion due to tuberculosis infection, as evidenced by one of the criteria, namely pleural effusion with a positive bacteriological examination for tuberculosis, including examination of acid fast staining, culture, or polymerase chain reaction (PCR) of pleural fluid, sputum, pleural tissue, or a rapid molecular test of sputum or pleural tissue; pleural tissue biopsy showing granulomatous tissue specific for tuberculosis; exudate pleural effusion with negative bacteriological examination but diagnosed clinically confirmed pulmonary tuberculosis and improved with anti-tuberculosis therapy; or exudate pleural effusion with negative bacteriological examination, pleural fluid analysis showed dominant lymphocytes and pleural fluid adenosine deaminase levels above 40 U/l. Patients with malignant pleural effusions were patients with pleural effusions due to primary or metastatic malignancy processes, as evidenced by one of the criteria, namely pleural fluid cytology obtained malignant cells; pleural biopsy found malignant cells; or exudate pleural effusion with malignancy in the lung or other organs and no other cause of pleural effusion.

The inclusion criteria were over 18 years of age, had not received chemotherapy or anti-tuberculosis therapy, and pleural puncture could be performed. Exclusion criteria were bacterial infection, empyema, severe infection and/or sepsis, and the presence of pleural puncture contraindications, namely extensive skin infection in the puncture area, and coagulopathy.

Patients with tuberculous and malignant pleural effusions who came to the polyclinic or inpatient room of Sanglah General Hospital underwent pleural punctures. Pleural fluid samples were examined for IL-6 levels with enzyme-linked immunosorbent assay (ELISA) method using the human IL-6 ELISA kit Elabscience, and leucocyte differential counts were examined using the cell-dyn hematology analyzer. From the pleural fluid leukocyte counts, the NLR and MLR were measured. Informed consent was obtained from all study subjects. Research ethics and permits are completed according to the provisions. The collected data was then processed using IBM statistical package for the social sciences (SPSS) statistics 2.0, namely the 2 independent sample t-test for the IL-6 mean, Mann Whitney test for NLR and MLR, and measuring area under curve (AUC) with receiver operating characteristic (ROC) curve.

RESULTS
In this study, 22 subjects with tuberculous pleural effusions and 31 subjects with malignant pleural effusions were found. The mean age of subjects with tuberculous pleural effusions was younger (31.18±16.68 years), while the mean age of those in malignant pleural effusions was 54.7±48.38 years. The majority of tuberculous pleural effusion subjects were male (72.7%), while the majority of malignant pleural effusion subjects were female (61.3%). The most common complaints in both groups were shortness of breath, cough, and weight loss. Complaints of fever were more common in tuberculous pleural effusion subjects (40.9%) than in malignant pleural effusion subjects (12.9%). In 71% of malignant pleural effusion subjects, breathlessness occurred with grade 4 modified Medical Research Council (mMRC) scale, whereas most
tuberculous pleural effusion subjects experienced grade 2 (40.9%) and grade 3 (50%). The results of the sputum molecular rapid test in the tuberculous pleural effusion subjects detected *Mycobacterium tuberculosis* in 36.4% of the subjects. The most common cause of malignant pleural effusion was pulmonary adenocarcinoma (45.2%), and 42.9% of these subjects had epidermal growth factor receptor (EGFR) mutations (Table 1). Pleural fluid analysis in subjects with tuberculous and malignant pleural effusions showed no significant difference (Table 2). The mean pleural fluid IL-6 in tuberculous pleural effusion subjects was 9269.017±902.211 pg/ml, and the mean pleural fluid IL-6 in subjects with malignant pleural effusions was 8212.146±2022.350 pg/ml. Using independent t-test, there was a significant difference between the two groups (p=0.014), with a mean difference of 1056.870 pg/ml. To diagnose tuberculous pleural effusion, using the ROC curve, an AUC of 66.6% (95% CI 51.9-81.4%) was obtained, p=0.04 (Figure 1). Using the ROC curve, the optimal cut-off point for pleural fluid IL-6 was obtained, which was the intersection of the sensitivity curve with the specificity curve. The optimal cut-off point was ≥9147.959 pg/ml, with sensitivity of 63.6% and specificity of 64.5% (Figure 2).

### Table 1: Demographic characteristics of tuberculous and malignant pleural effusion subjects.

| Characteristics                        | Tuberculous pleural effusions (n=22) | Malignant pleural effusions (n=31) | P value |
|----------------------------------------|--------------------------------------|-----------------------------------|---------|
| Age (years), mean ± SD                 | 37.18±16.68                          | 54.71±8.38                        | 0.000   |
| Gender, n (%)                          |                                      |                                   | 0.015   |
| Male                                   | 16 (72.7)                            | 12 (38.7)                         |         |
| Female                                 | 6 (27.3)                             | 19 (61.3)                         |         |
| Body mass index (kg/m²), mean±SD       | 19.54±2.90                           | 20.94±3.20                        | 0.111   |
| Smoking, n (%)                         |                                      |                                   | 0.553   |
| Smoker                                 | 8 (36.4)                             | 8 (25.8)                          |         |
| Passive smoker                         | 9 (40.9)                             | 12 (38.7)                         |         |
| Non-smoker                             | 5 (22.7)                             | 11 (35.5)                         |         |
| Symptoms, n (%)                        |                                      |                                   |         |
| Shortness of breath                    | 22 (100)                             | 31 (100)                          |         |
| Cough                                  | 21 (95.5)                            | 29 (93.5)                         |         |
| Chest pain                             | 7 (31.8)                             | 12 (38.7)                         |         |
| Fever                                  | 9 (40.9)                             | 4 (12.9)                          |         |
| Weight loss                            | 19 (86.4)                            | 27 (87.1)                         |         |
| mMRC scale, n (%)                      |                                      |                                   |         |
| Grade 1                                | 1 (4.5)                              | 0 (0)                             |         |
| Grade 2                                | 9 (40.9)                             | 2 (6.5)                           |         |
| Grade 3                                | 11 (50)                              | 7 (22.6)                          |         |
| Grade 4                                | 1 (4.5)                              | 22 (71)                           |         |
| Sputum rapid molecular test, n (%)     |                                      |                                   |         |
| MTB detected                           | 8 (36.4)                             |                                   |         |
| MTB not detected                       | 14 (63.6)                            |                                   |         |
| Tumor diagnosis, n (%)                 |                                      |                                   |         |
| Lung adenocarcinoma                    | 14 (45.2)                            |                                   |         |
| EGFR mutation, n (%)                   | 6 (42.9)                             |                                   |         |
| Wild type                              | 6 (42.9)                             |                                   |         |
| Unknown                                | 2 (14.3)                             |                                   |         |
| Squamous cell lung carcinoma           | 5 (16.1)                             |                                   |         |
| Breast carcinoma                       | 3 (9.7)                              |                                   |         |
| Ovarian carcinoma                      | 2 (6.5)                              |                                   |         |
| Non Hodgkin lymphoma                   | 2 (6.5)                              |                                   |         |
| Thyroid carcinoma                      | 1 (3.2)                              |                                   |         |
| Cervical carcinoma                     | 1 (3.2)                              |                                   |         |
| Endometrial carcinoma                  | 1 (3.2)                              |                                   |         |
| Non-small cell lung carcinoma          | 1 (3.2)                              |                                   |         |
| Carcinoma with neuroendocrine feature  | 1 (3.2)                              |                                   |         |

SD=standard deviation; mMRC=modified Medical Research Council; MTB=*Mycobacterium tuberculosis*; EGFR=epidermal growth factor receptor
The median NLR of pleural fluid in tuberculosis pleural effusion subjects was 0.065 (0.010-0.254). Median NLR and MLR of pleural fluid in both groups were not significantly different (p=0.807 and p=0.116, respectively).

### DISCUSSION

In this study, the mean age of subjects with tuberculous pleural effusions was younger than the mean age of subjects with malignant pleural effusions. Malignant pleural effusion is more common in elderly, which is associated with higher prevalence of malignancy in elderly due to genomic instability, epigenetic changes, and loss of proteostasis. Tuberculosis is frequent in young people due to more outdoor activities at productive age.

The majority subjects with tuberculous pleural effusions were male, whereas the majority subjects with malignant pleural effusions were female. This is associated with higher tuberculosis infection in males, due to more outdoor activity, smoking habit and alcohol consumption. Moreover, there is worse stigma in women with tuberculosis, thereby reducing willingness to seek treatment. Research by Hertz et al stated that in mice infected with tuberculosis, follicular B lymphocytes were smaller and interleukin-23 expression was lower in male mice, which had an effect on disease progression. More malignant pleural effusions in women were associated with pulmonary adenocarcinoma as the highest cause. EGFR mutations are more common in women, and the estrogen receptor α (ERα) affects adenocarcinoma progression. In this study, malignant pleural effusions were also caused by breast, ovarian, cervical, and endometrial tumors, thus affecting the high frequency of female subjects in this group.

The most common cause of malignant pleural effusion was pulmonary adenocarcinoma, with EGFR mutations detected in 42.9% of subjects with pulmonary adenocarcinoma. Research by Yang et al stated that EGFR mutations were detected in 70% of patients with pleural effusions due to pulmonary adenocarcinoma, and most were exon 19 deletions.

### Table 2: Pleural fluid characteristics of tuberculous and malignant pleural effusion subjects.

| Characteristics                          | Tuberculous pleural effusions (n=22) | Malignant pleural effusions (n=31) | P value |
|-----------------------------------------|--------------------------------------|-----------------------------------|---------|
| Pleural fluid pH, median (range)        | 8.0 (7.0-8.0)                        | 8.0 (7.0-8.0)                     | 0.963   |
| Leucocyte count/mm, mean ± SD           | 2237±1663                            | 1597±1390                         | 0.135   |
| Pleural fluid glucose (mg/dl), mean±SD  | 74.55±32.36                         | 75.31±31.17                       | 0.931   |
| Pleural fluid total protein (g/dl), mean±SD | 4.70±0.98                          | 4.23±1.11                         | 0.117   |
| Pleural fluid LDH (U/L), median (range) | 583.5 (189-11469)                    | 1037 (41-34012)                   | 0.448   |
| Pleural fluid neutrophil count (10³/ul), median (range) | 0.101 (0.009-13.100) | 0.218 (0.008-2.576) | 0.594   |
| Pleural fluid lymphocyte count (10³/ul), median (range) | 1.020 (0.155-6.850) | 0.933 (0.227-3.530) | 0.957   |
| Pleural fluid monocyte count (10³/ul), median (range) | 0.069 (0.013-0.990) | 0.058 (0.008-0.205) | 0.216   |

SD = standard deviation; LDH = lactate dehydrogenase
In this study, mean pleural fluid IL-6 was significantly higher in subjects with tuberculous pleural effusions than in malignant pleural effusions. This is related to the significant role of IL-6 in tuberculosis infection which has pro-inflammatory and anti-inflammatory effects, especially in the early phase. *Mycobacterium tuberculosis*, which is phagocytized by macrophages and survives in macrophages, will induce the production of various inflammatory mediators, including IL-6. IL-6 is produced by T lymphocytes, B lymphocytes, phagocytes, fibroblasts, and endothelial cells. In a later stage, IL-6 plays a role in the formation and stability of granulomas. IL-6 also induces T and B lymphocyte responses, as well as hematopoiesis. Mice that cannot produce IL-6 experience higher growth of *Mycobacterium tuberculosis*, especially in the early phase, and late induction of interferon gamma.

Subjects with malignant pleural effusions had a fairly high range of IL-6 levels, namely 2438.776 pg/ml to 1137.755 pg/ml. This can be related to various mechanisms for malignant pleural effusions, including pleural metastases, mediastinal lymph node involvement, bronchial obstruction, pericardial involvement, hypoproteinemia, obstructive pneumonitis, and pulmonary embolism. The second cause is different levels of IL-6 in various malignancies. In addition, pleural fluid IL-6 levels were associated with the progression of tumor infiltration in the pleural cavity. IL-6 plays a role in increasing the invasiveness of tumor cells, metastasis and angiogenesis by increasing the expression of matrix metalloproteinase-2 (MMP-2), vascular endothelial growth factor (VEGF), and fibroblast growth factor. Elevated IL-6 levels are associated with increased tumor staging, metastases, and poor prognosis. Therefore, varying levels of IL-6 pleural fluid in malignant pleural effusions can arise in varying tumor progression, stage, and metastases in the pleural space.

NLR is the ratio of absolute neutrophils to lymphocytes, and generally neutrophil levels correlate with the degree of inflammation and disease progression, whereas lymphocytes correlate with the body's defense system against disease. Research by Akturk et al in 2016 stated that pleural fluid NLR was lower in tuberculous pleural effusions than malignant pleural effusions. In this study, pleural fluid NLR was higher in subjects with malignant pleural effusions than tuberculosis pleural effusions, but not significantly different. This can be caused by an increase in pleural fluid neutrophils in tuberculous pleural effusions, especially in the early and late phases. Pleural fluid in tuberculous pleural effusions is generally lymphocyte dominant. In patients with symptoms less than 2 weeks, pleural fluid is dominated by polymorphonuclear cells. Over time, lymphocytes will increase with a lymphocyte-neutrophil ratio of 0.75. But at an advanced stage, especially when loculation and empyema arise, neutrophil will dominate in the pleural fluid. In mice with tuberculosis infection, lung tissue neutrophils increase in 2 waves, namely on day 3 and day 23-56. Neutrophils have 2 opposite effects, namely in the initial phase increasing the movement of dendritic cells to the lymph nodes, increasing the initiation of CD4 T lymphocyte activation, and forming granulomas. Whereas in the advanced phase, the increase in neutrophils is associated with disease progression and tissue damage.

There are several factors that influence pleural fluid neutrophil level; the first is a history of smoking. Pleural fluid neutrophil levels were increased in smokers (1-14%) compared to non-smokers (0-3%). In this study, pleural fluid NLR levels were higher in the smoker group, but not significantly different. The second factor is the pleural drainage device which can play a role in the inflammatory process in the pleural cavity. In this study, there were 3 subjects with a history of using indwelling pleural catheters (IPC) in malignant pleural effusion subjects, and 7 subjects with history of chest tube insertions in tuberculous pleural effusion subjects. The third factor is repeated pleural puncture. Research by Chung et al stated that the pleural fluid neutrophil levels in malignant pleural effusions increased with repeated pleural punctures, whereas the levels of lymphocytes and macrophages were not different.

MLR is the ratio of absolute monocytes to lymphocytes. In this study, the median MLR of pleural fluid in subjects with tuberculosis pleural effusions and malignant pleural effusions was not significantly different. No previous research used MLR as a parameter to differentiate tuberculosis pleural effusions from malignant pleural effusions. Previous studies used MLR to determine immune deficiency status, the body's immune response to *Mycobacterium tuberculosis* infection, and to evaluate the prognosis for malignancy. Research by Guadagnino et al stated that blood MLR was significantly increased in tuberculosis patients compared to healthy individuals. Another research by Sampath et al stated that the tuberculin test together with MLR could be used as a predictor of tuberculosis infection in individuals with a history of contact. Whereas in malignancy, the research by Lim et al stated that in stage 4 non-small cell lung carcinoma with malignant pleural effusions, the combination of platelets and lymphocyte to monocyte ratio acted as a marker of inflammation and a predictor of poor prognosis.

Monocytosis have a role in the pleural inflammatory process in tuberculous pleural effusions and malignant pleural effusions. In tuberculous pleural effusions, monocytosis differentiate into macrophages become the first line of defence by differentiating into M1 macrophages, which play a role in producing pro-inflammatory cytokines and a bactericidal response to *Mycobacterium tuberculosis*, and forming granulomas in the advanced phase. In malignant pleural effusions, macrophages modulate proliferation and T lymphocyte differentiation. Tumor associated macrophages (TAMs) decrease cytotoxicity, increase tumor cell growth and decrease immune response.
Lymphocytes act as adaptive immunity to tuberculous and malignant pleural effusions. In tuberculous pleural effusions, there is a decrease in Th1 lymphocyte response, leading to decreased production of interferon gamma and interleukin-12 which exacerbates infection.\(^2^9\) In malignant pleural effusions, the CD4+/CD8+ ratio increases more than 2.2 with an increase in CD4+ memory T cells and a decrease in T cells CD8+ effectors, which play a role in immune escape by tumor cells.\(^1^9\)

The age and sex of subjects with tuberculous and malignant pleural effusions differed significantly between the two groups. To see the effect of gender on pleural fluid NLR and MLR of the two groups, an analysis of pleural fluid NLR and MLR was carried out in male and female subjects in both groups, and the results were that pleural fluid NLR and MLR were not significantly different between men and women in tuberculous pleural effusions and malignant pleural effusions. To see the effect of age on pleural fluid NLR and MLR in both groups, analyses of pleural fluid NLR and MLR were carried out in subjects with a homogenous age range of 40-60 years in both groups, and the results stated that pleural fluid NLR and MLR of tuberculous and malignant pleural effusion subjects were not significantly different in this age range.

The weakness of this research was that the effect of interventions in the pleural cavity that cause changes in inflammatory parameters in the pleural cavity were not evaluated, namely the installation of pleural fluid drainage devices (chest tube and indwelling pleural catheter) and repeated pleural punctures.

**CONCLUSION**

In conclusion, pleural fluid IL-6 levels are significantly higher in tuberculous pleural effusions than in malignant pleural effusions. With pleural fluid IL-6 levels \(\geq 9147.959\) pg/ml, tuberculous pleural effusions can be diagnosed with a sensitivity of 63.6% and a specificity of 64.5%. There is no difference between RNL and RML pleural fluid in tuberculous pleural effusions and malignant pleural effusions. Future studies can use pleural fluid IL-6 levels in combination with other inflammatory parameters to differentiate tuberculous pleural effusions and malignant pleural effusions, and take into account confounding variables, namely interventions in the pleural cavity that can affect inflammatory parameters in the pleural cavity, including the installation of a pleural fluid drainage device, and recurrent pleural punctures.

**ACKNOWLEDGEMENTS**

Authors are grateful to all staffs of Udayana University and Sanglah General Hospital who have helped to complete the research and writing of this article.

*Funding: No funding sources
Conflict of interest: None declared
Ethical approval: The study was approved by the Institutional Ethics Committee*

**REFERENCES**

1. Light RW. Pleural effusions. Med Clin North Am. 2011;95(6):1055-70.
2. Surjanto E, Sutanto YS, Aphridiasari J. Penyebab efusi pleura pada pasien rawat inap di rumah sakit. J Respir Indo. 2014;34(2):102-8.
3. Dwianggita P. Etiologi efusi pleura pada pasien rawat inap di Rumah Sakit Umum Pusat Sanglah, Denpasar, Bali tahun 2013. ISM. 2016;7(1):57-66.
4. Soeratman E, Jayusman AM, Hanafi AR, Hanif MA. Efusi pleura ganas. In: Rasmin M, Jusuf A, Amin M, Taufik, Nawas MA, Rai IBN, et al, eds. Buku Ajar Pulmonologi dan Kedokteran Respirasi. Jakarta: UI Publishing. 2018:65-80.
5. De-Groot PM, Wu CC, Carter BW, Munden RF. The epidemiology of lung cancer. Transl Lung Cancer Res. 2018;7(3):220-33.
6. Kiropoulos TS, Kostikas K, Oikonomidi S, Tsilioni I, Nikoulis D, Germenis A, et al. Acute phase markers for the differentiation of infectious and malignant pleural effusions. Respir Med. 2007;101(5):910-8.
7. El-Sayed R, Okab A, El-Mahdy M, Kasb I, Ismail Y. Role of interleukin-6 (IL-6) in diagnosis of malignant pleural mesothelioma. Egypt J Chest Dis Tuberc. 2015;64(2):419-24.
8. Akturk U, Ernam D, Akbay MO, Kocak ND, Ogur E, Irmak I. Role of the Neutrophil-Lymphocyte Ratio in the differential diagnosis of exudative pleural effusion. Clinics. 2016;71(10):611-6.
9. Guadagnino G, Serra N, Colomba C, Giannanco A, Mililli D, Scarlata F, et al. Monocyte to lymphocyte blood ratio in tuberculosis and HIV patients: Comparative analysis, preliminary data. Pharmacologyonline. 2017;1:22-33.
10. Aunan JR, Cho WC, Soreide K. The Biology of aging and cancer: A brief overview of shared and divergent molecular hallmarks. Aging Dis. 2017;8(5):628-42.
11. World Health Organization. Tuberculosis fact sheets, 2020. Available at: https://www.who.int/news-room/fact-sheets/detail/tuberculosis. Accessed on: 30 November 2020.
12. World Health Organization. Gender and tuberculosis. 2002. Available at: https://www.who.int/gender-equity-rights/knowledge/a85584/en/. Accessed on: 30 November 2020.
13. Hertz D, Dibbern J, Eggers L, von Borstel L, Schneider BE. Increased male susceptibility to Mycobacterium tuberculosis infection is associated with smaller B cell follicles in the lungs. Sci Rep. 2020;10:5142.
14. Mazieres J, Rouquette I, Lepage B, Milia J, Brouchet, Guibert N, et al. Specificities of lung adenocarcinoma in women who have never smoked. J Thorac Oncol. 2013;8(7):923-9.
15. Yang J, Lee O, Son S, Woo CG, Jeong Y, Yang Y, et al. EGFR mutation status in lung adenocarcinoma-associated malignant pleural effusion and efficacy of
EGFR tyrosine kinase inhibitors. Cancer Res Treat. 2018;50(3):908-16.
16. Zuniga J, Torres-Garcia D, Santos-Mendoza T, Rodriguez-Reyna TS, Granados J, Yunis EJ. Cellular and humoral mechanisms involved in the control of tuberculosis. Clin Dev Immunol. 2012;193923:1-8.
17. Saunders BM, Frank AA, Orme IM, Cooper AM. Interleukin-6 induces early Gamma Interferon production in the infected lung but is not required for generation of specific immunity to Mycobacterium tuberculosis infection. Infect Immun. 2000;68(6):3322-6.
18. Light RW. Pleural effusions related to metastatic malignancies. In: Light RW, Pleural Diseases. 6th ed. Philadelphia: Lippincott Williams & Wilkins. 2013;153-88.
19. Murthy P, Ekeke CN, Russell KL, Butler SC, Wang Y, Luketich JD. Making cold malignant pleural effusions hot: driving novel immunotherapies. Oncoimmunology. 2019;8(4):e1554969.
20. Shaw JA, Diacon AH, Koegelenberg CFN. Tuberculous pleural effusion. Respiriology. 2019;24:962-71.
21. Lyadova IV. Neutrophils in tuberculosis: Heterogeneity shapes the way? Mediators Inflamm. 2017;8619307.
22. Noppen M, De Waele M, Li R, Gucht KV, D’Haese J, Gerlo E, et al. Volume and cellular content of normal pleural fluid in humans examined by pleural lavage. Am J Respir Crit Care Med. 2000;162:1023-6.
23. De Smedt A, Vanderlinden E, Demanet C, De Waele M, Goosens A, Noppen M. Characterisation of pleural inflammation occurring after primary spontaneous pneumothorax. Eur Respir J. 2004;23:896-900.
24. Chung C, Chen Y, Chang S. Effect of repeated thoracenteses on fluid characteristics, cytokines, and fibrinolytic activity in malignant pleural effusion. Chest. 2003;123:1188-95.
25. Sampath P, Moideen K, Ranganathan UD, Bethunaickan R. Monocyte subsets: Phenotypes and function in tuberculosis infection. Front Immunol. 2018;9:1726.
26. Lim JU, Yeo CD, Kang HS, Park CK, Kim JS, Kim JW, et al. Prognostic value of platelet count and lymphocyte to monocyte ratio combination in stage IV non-small cell lung cancer with malignant pleural effusion. PLoS One. 2018;13(7):e0200341.
27. McClean CM, Tobin DM. Macrophage form, function, and phenotype in mycobacterial infection: lessons from tuberculosis and other diseases. Pathog Dis. 2016;74(7):68.
28. Romero-Adrian TB, Leal-Montiel J, Fernandez G, Valecillo A. Role of cytokines and other factors involved in the Mycobacterium tuberculosis infection. World J Immunol. 2015;5(1):16-50.

Cite this article as: Singgih V, Suryana K, Kusumawardani IAJD, Candrawati NW, Sajinadiyasa IGK, et al. Role of pleural fluid interleukin-6, neutrophil-lymphocyte ratio, and monocyte-lymphocyte ratio in distinguishing tuberculous and malignant pleural effusions. Int J Adv Med 2021;8:492-8.